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A major current deficit in structural biology is the lack
of high-resolution structures of eukaryotic mem-
brane proteins, many of which are key drug targets
for the treatment of disease. Numerous eukaryotic
membrane proteins require specific lipids for their
stability and activity, and efforts to crystallize and
solve the structures of membrane proteins that do
not address the issue of lipids frequently end in fail-
ure rather than success. To help address this prob-
lem, we have developed a sparse matrix crystalliza-
tion screen consisting of 48 lipidic-sponge phase
conditions. Sponge phases form liquid lipid bilayer
environments which are suitable for conventional
hanging- and sitting-drop crystallization experi-
ments. Using the sponge phase screen, we obtained
crystals of several different membrane proteins from
bacterial and eukaryotic sources. We also demon-
strate how the screen may be manipulated by incor-
porating specific lipids such as cholesterol; this
modification led to crystals being recovered from
a bacterial photosynthetic core complex.
INTRODUCTION
Membrane proteins are challenging targets for structural studies
and require careful biochemical treatment. Prior to purification
and crystallization, membrane proteins must be solubilized
with detergent and are typically purified using hydrophobic chro-
matography resins. Purification thus often causes specific lipids
to be removed from the protein’s surface and impairs structural
integrity. As a consequence, membrane proteins often display
reduced activity and poor stability in detergent solution. Never-
theless, membrane proteins can be stabilized by incorporating
specific lipids within the detergent micelle which has, in certain
cases, facilitated efforts to crystallize them (Guan et al., 2007;
Kurisu et al., 2003).Structure 16An alternative approach is to reconstitute purified membrane
proteins into a lipidic-cubic phase (LCP) environment, a semi-
solid bicontinuous lipid matrix that contains extended water
channels, which returns the protein to a membrane-like environ-
ment. Once incorporated into the LCP, proteins can then be
crystallized (Landau and Rosenbusch, 1996). Using the LCP
methodology, crystal structures havebeen reported for a number
of proteins including bacteriorhodopsin (Belrhali et al., 1999;
Luecke et al., 1999; Pebay-Peyroula et al., 1997), halorhodopsin
(Kolbe et al., 2000), sensory rhodopsin (Gordeliy et al., 2002;
Royant et al., 2001; Vogeley et al., 2004), bacterial photosyn-
thetic reaction centers (Chiu et al., 2000; Katona et al., 2003,
2005), the cobalamin transporter BtuB (Misquitta et al., 2004),
and the b2-adrenergic receptor (Cherezov et al., 2007; Rosen-
baum et al., 2007), which was the first structure of a ligand-
activated G protein-coupled receptor.
Despite these successes, there are several practical draw-
backs when using LCPs for membrane protein crystallization.
In particular, the aqueous pores in the LCP are rather small, po-
tentially preventing the incorporation of membrane proteins with
large hydrophilic domains, and is highly viscous and therefore
cannot easily be used in vapor-diffusion experiments. There
are also difficulties when visualizing the crystallization experi-
ment and interpreting the results, making harvesting of crystals
problematic such that lipase or detergent is frequently added
to liquefy the LCP prior to crystal fishing (Nollert and Landau,
1998). For these reasons, the LCP crystallization technique is
not readily compatible with high-throughput crystallization
approaches.
To overcome these problems, we have utilized a phase related
to the LCP called the (lipidic-)sponge or L3 phase. This phase can
be obtained by adding a solvent such as polyethyleneglycol
(PEG), 2-methyl-2,4-pentanediol (MPD), or jeffamine M600 to a
lipid:water system, causing it to swell. The aqueous pores in a
sponge phase are up to three times larger than those in a lipidic-
cubic phase, allowing them to accommodatemembrane proteins
with large extra- and/or intracellular domains (Engstro¨m et al.,
1998). The most obvious practical advantage of this approach is
that the lipidic-sponge phase is liquid at room temperature and
can be used directly in hanging- or sitting-drop vapor-diffusion, 1003–1009, July 2008 ª2008 Elsevier Ltd All rights reserved 1003
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compatible with the use of commercially available crystallization
robots and greatly facilitates the mounting of protein crystals in
nylon loops. Using lipidic-sponge phase crystallization, X-ray
structures of a photosynthetic reaction center (Wadsten et al.,
2006), a light-harvesting complex (Cherezov et al., 2006a), and a
bacterial transporter (Cherezov et al., 2006b) have recently been
reported.
To further harness the potential of lipidic-sponge phase crys-
tallization for determining new membrane protein structures, we
have designed a sponge phase sparse matrix crystallization
screen consisting of 48 different conditions. Moreover, the use-
fulness of this screen has been validated against a range of
bacterial and eukaryotic membrane proteins. Initial crystal leads
were obtained for 8 proteins out of 11 tested, demonstrating the
screen’s effectiveness.
RESULTS
Conceptualization of a Sponge Phase
Crystallization Screen
This work aimed to establish and validate a lipidic-sponge phase
crystallization screen consisting of 48 experimental conditions.
We conceptualized this screen using the most popular crystalli-
zation agents, buffers, and salts which have proven successful
for conventional membrane protein crystallization (Iwata, 2003;
Newstead et al., 2008) in combination with previously successful
sponge phase crystallization conditions (Wadsten et al., 2006).
Other prerequisites were that the sponge phases were stable
over time at room temperature and that the pH range of the
screen was restricted to between 5.5 and 9.0, as the ester
bond of the lipid monoolein (MO) is sensitive to hydrolysis at
extreme pH values (Engstro¨m et al., 2007).
Lipidic-sponge phases can be obtained by mixing MO with
a buffer solution such as MES, HEPES, or Tris, and a crystalliza-
tion agent, such as PEG, MPD, or jeffamine M600. Salt can also
be added to the buffer and its pH varied, allowing a broad variety
of distinct sponge phases to be formed. PEG 400 is one of the
most commonly used precipitants in membrane protein crystal-
lization (Newstead et al., 2008) and was therefore chosen as
a central ingredient in the design of the sponge phase screen.
The phase diagram of the PEG 400:MO:water system shows
that sponge phases form with approximately 30% water and
with MO and PEG 400 in the range of 5%–40% and 30%–
65%, respectively (Engstro¨m et al., 1998; Ridell et al., 2003).
From this starting point, a series of sponge phases were created
using the buffers MES, HEPES, and Tris and the salts NaCl,
MgCl2, and Li2SO4. Incorporation of salt into the sponge phases
caused them to become more fluid, making them easier to han-
dle. Sponge phases with PEG 1500 and PEG 4000 were also
formed under similar conditions as those for PEG 400. This is
not unexpected, as the phase diagrams for PEG 400, 1500,
and 4000 are largely similar (Ridell, 2003). For MPD, it is known
that MPD sponge phases form in the range of 50%–70% water,
12%–43% MO and 7%–18% MPD (Ridell et al., 2003). Thus, in
contrast to the PEG sponge phases, the water content of MPD
sponge phases is not constant.
Using the crystallization agent jeffamine M600, we previously
reported well-diffracting crystals of the Rhodobacter sphaer-1004 Structure 16, 1003–1009, July 2008 ª2008 Elsevier Ltd All righoides reaction center grown directly from the sponge phase
(Wadsten et al., 2006). In that work, because the phase diagram
of the jeffamine M600:MO:water system is not known, we first
made an LCP upon which jeffamine M600, at a concentration
between 12% and 20%, was added. This caused the LCP to
swell and resulted in the formation of two liquid phases, of which
the upper was the sponge phase. As with the PEG conditions,
the sponge phases recovered using this protocol could be
varied by altering the pH, or changing the salt and reagent
concentrations.
Once a variety of stable liquid lipidic phases were recovered
using PEG 400, 1500, and 4000, MPD, and jeffamine M600, we
established whether or not they had the physical characteristics
of a sponge phase. As lipidic-sponge phases are nonbirefrin-
gent, a simple but effective analysis using polarized light was first
applied to test the phase. Further characterization of samples
lacking birefringence was pursued using small-angle X-ray scat-
tering (SAXS). Sponge phases show one broadBragg peak in the
SAXS diagram, which stems from the lack of long-range order,
whereas LCPs have distinct, ordered peaks (Engstro¨m et al.,
2007). Sponge phase conditions with MPD as a crystallization
agent (Ridell et al., 2003) showed the broad Bragg peak along
with distinct peaks indicating the presence of other phases.
These phases did not yield crystal leads and were therefore
not considered further in developing the screen. For all condi-
tions finally selected, broad Bragg peaks were observed, indi-
cating that they all form lipidic-sponge phases. A representative
set of SAXS diffractogram is presented in Figure 1 for each of the
solvents included in the final screen.
Testing the Sponge Phase Crystallization Screen
The value of the sponge phase for generating membrane protein
crystals was investigated in a series of hanging-drop crystalliza-
tion experiments. All crystallization trials were performed at room
temperature (20C), as sponge phases may spontaneously re-
vert to a lamellar phase at 4C (Wadsten et al., 2006). Purified tar-
get proteins, from both bacterial and eukaryotic sources, were
mixed with the sponge phases in a 1:1 ratio and equilibrated in
a sealed container against a reservoir solution. Because the
Figure 1. Small-Angle X-Ray Scattering Data
SAXS diffraction patterns of representative samples incorporating all of the
crystallization agents PEG 400, PEG 1500, PEG 4000, and jeffamine M600
used in the sponge phase screen. For all four solvents, diffuse Bragg peaks
can clearly be observed, confirming that these samples are sponge phases.ts reserved
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Number Protein Source Abbreviation
MW
(kDa) TM Detergent
Protein
Concentration
(mg/ml)
Crystallization
Conditions
1 Aquaporin Plasmodium falciparum PfAQP 30 6 DDM 10–15 30
2 Aquaporin Spinacia oleracea SoPIP2;1 30 6 b-OG 10–15 4
3 Complex II Bacillus subtilis BsSQR 120 6 Thesit 10–20 40
4 Proteorhodopsin g-proteobacterium pR 27 7 b-OG DDM 10–20 -
5 Bacteriorhodopsin Halobacterium salinarium bR 27 7 b-OG 7.5–12.5 -
6 Reaction center Rhodobacter sphaeroides RCsph 100 11 LDAO 20–25 31, 36, 37, 43
7 Reaction center Blastochloris viridis RCvir 135 11 LDAO 20–25 19, 31, 32, 36, 37
8 Light-harvesting
complex 2
Rhodopseudomonas
acidophila
LH2aci 150 18 LDAO 5 25, 31, 38, 45
9 Ubiquinol oxidase Escherichia coli UbOx 144 25 DDM 10 -
10 Light-harvesting
complex 2
Rhodobacter
sphaeroides
LH2sph Unknown Unknown LDAO 5 4
11 Photosynthetic core
complex
Blastochloris viridis RC-LH1vir 440 43 CHAPS 20–25 36
Complete list of membrane proteins used for testing the lipidic-sponge phase crystallization screen. For each membrane protein its source, molecular
weight (MW), number of transmembrane helices (TM), purification detergent, protein concentration for crystal trials, and successful crystallization con-
ditions are provided (Table S1).reservoir solution is not applied to the protein drop, it is not
necessary to include MO or vary the reservoir solution. As
such, all crystallization experiments were suspended over the
same reservoir solution (see the Experimental Procedures),
which was adapted from Chiu et al. (2000) with minor changes.
Nevertheless, the osmolarity of the reservoir solution will influ-
ence the rate of water diffusion and may therefore affect crystal
growth. One obvious variation for extending the screen to 96
conditions is therefore to equilibrate crystallization drops against
distinct buffers with different osmolarities. In our experiments, it
was not uncommon for crystals to take four or more weeks to
first appear.
Eleven different membrane proteins were used to validate
the lipidic-sponge phase method (Table 1). Crystal leads were
obtained for eight of these proteins (Figure 2A): aquaporin from
Plasmodium falciparum (PfAQP) and Spinacia oleracea
(SoPIP2;1), complex II from Bacillus subtilis (BsSQR), the photo-
synthetic reaction centers from Rhodobacter sphaeroides
(RCsph) and Blastochloris viridis (RCvir), the two light-harvesting
complexes from Rhodopseudomonas acidophila (LH2aci) and
R. sphaeroides (LH2sph) and the photosynthetic core complex
from Bl. viridis (RC-LH1vir). No crystal leads were recovered
from proteorhodopsin (pR), bacteriorhodopsin (bR), or ubiquinol
oxidase (UbOx). From these results, 48 lipidic-sponge phase
conditions were selected to form the crystallization screen, and
these are detailed in Table S1 available online. A graphical repre-
sentation of the pH distribution (Figure 3A) and the number of
conditions using each crystallization agent (Figure 3B) is also
presented for the final screen.
Sponge Phases and Additives: Optimization
of RCvir Crystals
To illustrate how the crystal screen can be used to recover
well-diffracting crystals, we describe the optimization of RCvir
crystals. Initial RCvir leads from the sponge phase screen wereStructure 1observed after 2 weeks in conditions 19, 31, 32, 36, and 37
(Table S1). Crystals were harvested directly from the sponge
phase and analyzed using X-rays to determine diffraction quality.
Crystals extracted from one of the jeffamine sponge phases
diffracted to 3.5 A˚ resolution equally well in all directions, with
well-defined diffraction spots indicative of a well-ordered crystal
(Figure 2B). This initial crystallization condition was further opti-
mized using Additive Screen HT (Hampton Research). The addi-
tion of sodium citrate tribasic dihydrate significantly improved
the size and quality of RCvir crystals (Figure 2C). These optimized
crystals diffracted to 1.8 A˚ and the structure of RCvir was solved
and refined (unpublished data). Thus, a generic approach
emerges such that, following the identification of promising con-
ditions using the sponge phase screen, crystal optimization can
be achieved through additive screening exactly as with other
popular crystallization methods (Iwata, 2003).
The Influence of Detergents
on Lipidic-Sponge Phase Stability
All membrane proteins used to test this screen were solubilized
in detergent prior to purification. The detergents used included
lauryldimethylamine-N-oxide (LDAO), n-octyl-b-D-glucopyrano-
side (b-OG), n-dodecyl-b-D-maltopyranoside (DDM), polyoxye-
thylene(9)dodecyl ether (Thesit), and 3-([3-cholamidopropyl]-
dimethylammonio)-1-propane sulfonate (CHAPS) (Table 1).
Although it is conceivable that the addition of detergents may
disrupt the lipidic-sponge phase during the crystallization pro-
cess, we did not observe any evidence to suggest this. Never-
theless, as a precaution, we recommend that detergents should
be used at a concentration marginally above their critical micelle
concentration. Control crystallization drop experiments using
three buffers with different detergents but lacking protein
showed one false positive crystal lead (condition 21) out of 144
conditions tested. This false lead appeared after 4 weeks. Al-
though this may be a special case, because two detergents6, 1003–1009, July 2008 ª2008 Elsevier Ltd All rights reserved 1005
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(A) Crystals were obtained for (1) plasmodium aquaporin, (2) spinach aquaporin, (3) complex II fromBacillus subtilis, (4) RC fromRhodobacter sphaeroides, (5) RC
from Blastochloris viridis, (6) LH2 from Rhodopseudomonas acidophila, (7) LH2 from R. sphaeroides, and (8) RC-LH1 from Bl. viridis, reading from left to right row
by row.
(B) Diffraction to 3.5 A˚ resolution recovered from crystals of RCvir grown in condition 37 of the screen.1006 Structure 16, 1003–1009, July 2008 ª2008 Elsevier Ltd All rights reserved
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without protein are always advisable.
Sponge Phases and Lipid Additives: Crystallization
of RC-LH1vir
Crystals of RC-LH1vir have previously been reported using lipid
additives (Ikeda-Yamasaki et al., 1998). Crystallization experi-
ments on RC-LH1vir were thus performed using a cholesterol-
doped variant of the sponge phase screen (see the Experimental
Procedures), and crystallization leads were recovered (Fig-
ure 2A). The convenience with which cholesterol or any other
lipid can be dissolved in molten MO and thereby incorporated
into sponge phases is highly advantageous and should facilitate
the crystallization of those membrane proteins whose structural
stability and activity have absolute lipid requirements (Cherezov
et al., 2007; Hanson et al., 2008).
DISCUSSION
From our results, 8 membrane proteins gave initial crystallization
leads of the 11 examined. Although this figure should be judged
with the caveat that structures of five of the crystal-yielding
Figure 3. pH and Solvent Distribution
Diagrams illustrating the pH distribution and crystallization agent composition
of the lipidic-sponge phase crystallization screen.
(A) Number of conditions between pH 5.5 and 9.0.
(B) Number of conditions for each of the crystallization agents PEG 400, PEG
1500, PEG 4000, and jeffamine M600.Structure 16membrane proteins have already been reported (Deisenhofer
et al., 1984; Papiz et al., 2003; Tornroth-Horsefield et al., 2006;
Wadsten et al., 2006; Newby et al., 2008), it is not unreasonable
to expect that changes in themembrane protein preparations for
bR (Michel and Oesterhelt, 1980) and UbOx (Abramson et al.,
2000), in particular, could ultimately generate leads using this ap-
proach. Because the membrane proteins which crystallized in-
cluded 6 transmembrane helices (TM) (SoPIP2;1; PfAQP;
BsSQR), 11 TM (RCvir; RCsph), 18 TM (LH2sph; LH2aci), and (pre-
sumably) 43 TM (RC-LH1vir) a-helical proteins and protein com-
plexes ranging in molecular weight from 30 to 440 kDa, this ap-
proach does not appear to be restricted to exceptionally stable
membrane proteins with small soluble domains. Rather, these
results point to a generic method which could easily be applied
to any challenge in membrane protein crystallization.
Three bacterial membrane protein structures have previously
been reported using the lipidic-sponge phase technique (Chere-
zov et al., 2006a, 2006b; Wadsten et al., 2006), and the rational
development of a convenient crystallization screen should signif-
icantly broaden the application of this technique. Our screen pro-
vides 48 distinct sponge phase conditions that can be used in
standard hanging- or sitting-drop vapor-diffusion crystallization
experiments. Initial hits can be optimized by the use of additive
screens and other standard crystallization protocols such as
the addition of ligands, inhibitors, cofactors, and enzyme sub-
strates and the variation of pH, salt, and crystallization agent
concentrations. Virtually any lipid of choice should be readily in-
corporated into a sponge phase at reasonable concentrations.
Thus, this characteristic is potentially critical for success in cer-
tain projects because the structural stability and activity of many
membrane proteins depend explicitly on specific lipids (Chere-
zov et al., 2007; Guan et al., 2007; Kurisu et al., 2003; Hanson
et al., 2008). Intuitively, sponge phases that more closely mimic
the protein’s native surroundings are those most likely to be suc-
cessful in the search for diffracting crystals.
EXPERIMENTAL PROCEDURES
Reagents
MO (1-mono-oleyl-rac-glycerol) used in the phase studies was obtained from
Danisco Cultor A/S (Brabrand, Denmark; 94.9% purity), whereas the MO used
in the crystallization trials was purchased from Nu-Chek Prep (Elysian, MN,
USA). Jeffamine M600 and the additive screen HR2-428 were purchased
from Hampton Research (La Jolla, CA, USA). 1,2,3-heptanetriol (high-melting
isomer), PEG 400, PEG 1500, and PEG 4000 were bought from Fluka Chemika
(Darmstadt, Germany). MPD was obtained from Merck (Hohenbrunn, Ger-
many). Glass vials and capswere purchased fromVWR (Darmstadt, Germany).
Preparation of the Sponge Phases
For the PEG- and MPD-containing sponge phases, MO was melted and
weighed into small glass vials along with the appropriate amount of PEG and
MPD, respectively, and the appropriate buffer solution. The vials were sealed
tightly and incubated on a roller for 1 day at 37C. In cases where the sample
was not homogeneous after this treatment, it was heated to 50C for 2–3 hr
and then reincubated at 37C. Afterwards, the samples were centrifuged
(20C, 5500 3 g, 35 min) and left until a transparent phase was observed.
Jeffamine sponge phases were prepared in a different manner because the
jeffamine M600:MO:water phase diagram is not known. MO was mixed in
a 60:40 volume ratio with 0.1 M HEPES (pH 7.5) until a viscous, transparent,(C) Improved diffraction, recorded from RCvir protein crystals after optimization using the Additive Screen HT (Hampton Research). The insert shows the mag-
nification of the spots diffracting to 1.8 A˚., 1003–1009, July 2008 ª2008 Elsevier Ltd All rights reserved 1007
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a glass vial, 1 ml of sponge phase-inducing solution (20% jeffamine M600,
1 M HEPES [pH 8.1], 0.7 M [NH4]2SO4, and 2.5% 1,2,3-heptanetriol) was
added. The sample was sealed and kept at room temperature until phase sep-
aration had fully occurred. After centrifugation (20C, 5500 3 g, 35 min), the
upper, sponge phase was harvested.
Cholesterol-doped sponge phases were prepared by dissolving 1% w/w of
cholesterol directly into molten MO. This doped MO was then further used to
prepare the sponge phases described above and used in crystallization exper-
iments. Similar protocols work well for ubiquinone and soya bean asolectin
and should work for almost any hydrophobic additive of choice.
Small-Angle X-Ray Diffraction Measurements
Samples of every sponge phase were examined using SAXS. Scattering data
were recorded by a Kratky camera (Hecus X-Ray Systems, Graz, Austria) with
a position-sensitive detector (MBraun, Garching, Germany) containing 1024
channels. An X-ray generator operated at 50 kV and 40 mA (Philips, PW
1830/40, Eindhoven, The Netherlands) was used to produce Cu Ka radiation
(l = 0.1542 nm). The sample-to-detector distance was 275 mm, and the expo-
sure time was typically 900 s for each sample. The temperature in the sample
cell was kept at 20C and was regulated by a Peltier element (accuracy ±
0.1C). The camera and the sample cell were held under vacuum to minimize
scattering from air. Diffractograms were evaluated using 3D-View software
(MBraun, Graz, Austria). Calibration of the instrument was performed using
solid tristearin.
Protein Crystallization Experiments
Lipidic-sponge phase conditions were tested with 11 different proteins (Table
1). For each protein, a series of hanging-drop vapor-diffusion experiments was
performed in which 1 ml of sponge phase was added to 1 ml of protein solution
on a glass cover slide. These drops were equilibrated against a reservoir
solution consisting of 0.1 g/l Na/KPO4, 0.55 M Na acetate, and 0.75 M HEPES
(pH 6.3). The plates were stored at 20C for several months. Protein crystals
typically appeared after 4 weeks.
RCvir Data Collection
RCvir crystals were fished directly from the sponge phase, without addition of
lipase or cryoprotectants, and flash-frozen in liquid nitrogen for X-ray analysis.
Data were collected at 100K with a MarCCD detector at beamline ID23-EH2 at
the European Synchrotron Radiation Facility (l = 0.873 A˚). The oscillation
range per image was 0.5. Data were indexed with MOSFLM 6.2.4 (Steller
et al., 1997). The crystals belong to space group P21212 with unit cell dimen-
sions of a = 84.9 A˚, b = 140.2 A˚, c = 178.8 A˚.
SUPPLEMENTAL DATA
Supplemental Data include one table and can be found with this article online
at http://www.structure.org/cgi/content/full/16/7/1003/DC1/.
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